NCT02203513: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

NCT02203513
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: All breast cancer subtypes are eligible for Cohort 1, but must have a BRCA germline (inherited) mutation OR somatic mutation expressed by the tumor. Only TNBC patients negative for the BRCA1/2 mutation and with no family history of hereditary breast and/or ovarian cancer are eligible for Cohort 2.
Exclusions: Patients with known active uncontrolled or symptomatic Central Nervous System (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT02203513

Comments are closed.

Up ↑